Hepatomegaly
Hepatomegaly
Explore linked clinical trials. Standard reference: MESH:M00102372 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Digestive System Diseases, Eosinophilia, Hemic and Lymphatic Diseases, Hepatomegaly, Hypertrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Splenomegaly, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, liver disorder | Active, not recruiting | Phase 2 | 2026-09-01 | NCT03801434 | |
| Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly | Chemically-Induced Disorders, Digestive System Diseases, Hepatomegaly, Hypertrophy, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, alcohol-induced disorders, alcohol-related disorders, alcoholic fatty liver disease, alcoholic liver disease, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease, substance-related disorder | Recruiting | Not applicable | 2025-07-23 | NCT07068191 |